Spravato in Sacramento

Spravato® (esketamine) is a prescription nasal spray approved by the FDA for adults with treatment-resistant depression and administered under direct medical supervision.

Spravato may be appropriate if you:

• Have tried two or more antidepressants without adequate relief
• Have been diagnosed with treatment-resistant depression
• Continue to experience significant depressive symptoms despite treatment

A psychiatric evaluation is required to determine whether Spravato is appropriate for you.

1. Psychiatric evaluation. A comprehensive visit to confirm Spravato is appropriate for you.
2. In-office administration. You self-administer the nasal spray at a certified treatment center under staff supervision.
3. Monitoring. At least two hours of observation after each dose, per FDA REMS requirements.
4. A treatment course. Typically twice-weekly sessions at first, tapering to a less frequent maintenance schedule as your provider directs.
5. Follow-up care. Ongoing appointments to track your response and adjust your plan.

Arrange a ride home for every session — you should not drive or operate machinery until the next day after a restful sleep.

Esketamine acts on NMDA receptors in the brain, increasing glutamate activity believed to help restore synaptic connections affected by depression — a different biological pathway than the serotonin- or norepinephrine-based mechanism of traditional antidepressants.